Adherence to Adjuvant Hormonal Therapy and Its Relationship to Breast Cancer Recurrence and Survival Among Low-income Women
Author:
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
Cancer Research,Oncology
Reference52 articles.
1. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.;Abe;Lancet,2005
2. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.;Goss;N Engl J Med,2003
3. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial.;Baum;Lancet,2002
4. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years adjuvant treatment for breast cancer.;Howell;Lancet,2005
5. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer.;Coombes;N Engl J Med,2004
Cited by 57 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Association between trajectories of adherence to endocrine therapy and risk of treated breast cancer recurrence among US nonmetastatic breast cancer survivors;British Journal of Cancer;2024-04-18
2. Identifying Complex Scheduling Patterns Amongst Cancer Patients with Transportation and Housing Needs (Preprint);2024-02-24
3. Digging in real-word electronic database for assessing CDK 4/6 inhibitors adherence in breast cancer patients from Romania;Frontiers in Pharmacology;2024-02-23
4. Importance of endocrine treatment adherence and persistence in breast cancer survivorship: a systematic review;BMC Cancer;2023-07-04
5. Survival benefits associated with being adherent and having longer persistence to adjuvant hormone therapy across up to five years among U.S. Medicare population with breast cancer;Breast Cancer Research and Treatment;2023-06-16
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3